Daily Sepsis Research Analysis
Analyzed 48 papers and selected 3 impactful papers.
Summary
Three high-impact studies advanced sepsis care today: an international Bayesian adaptive RCT found cefazolin noninferior to antistaphylococcal penicillins for methicillin-susceptible infections with less acute kidney injury; a Lancet Child & Adolescent Health RCT showed individualized, shorter antibiotic courses for culture-negative early-onset neonatal sepsis were safe and reduced exposure; and engineered complement-activating antibodies (T-CAT) bypassed bacterial immune evasion and protected mice from lethal sepsis.
Research Themes
- Antimicrobial stewardship and optimized antibiotic selection
- Therapeutic immunoengineering to overcome bacterial immune evasion
- Adaptive randomized trial designs in infectious diseases
Selected Articles
1. Cefazolin for Methicillin-Susceptible
In an international Bayesian adaptive, open-label randomized comparison, cefazolin achieved noninferior 90-day mortality versus antistaphylococcal penicillins and significantly reduced acute kidney injury. Probabilities strongly favored noninferiority for mortality and superiority for kidney safety.
Impact: This large adaptive RCT addresses a long-standing question in MSSA treatment and demonstrates a safer beta-lactam option without compromising survival.
Clinical Implications: For methicillin-susceptible Staphylococcus aureus infections presenting with sepsis or bacteremia, cefazolin can be prioritized over antistaphylococcal penicillins to minimize nephrotoxicity while maintaining outcomes. Institutions should update empiric/definitive therapy pathways accordingly.
Key Findings
- 90-day mortality: 15.0% (cefazolin, 97/645) vs 17.0% (anti-staphylococcal penicillin, 109/642); adjusted OR 0.81 (95% CrI 0.59–1.12); probability of noninferiority 99.2%.
- Acute kidney injury: 13.9% (92/660) vs 19.6% (127/648); adjusted OR 0.67 (95% CrI 0.50–0.89); probability of superiority 99.7%.
- Bayesian adaptive platform domain met noninferiority criterion between Feb 2022 and Aug 2024.
Methodological Strengths
- International Bayesian adaptive platform design with prespecified noninferiority and superiority probabilities.
- Large randomized sample with clinically meaningful endpoints (90-day mortality, acute kidney injury).
Limitations
- Open-label design may introduce performance bias.
- Abstract truncation limits clarity on infection syndromes and full protocol details.
Future Directions: Subgroup analyses (e.g., endocarditis, high-inoculum infections), pharmacokinetic-pharmacodynamic correlates, and cost-effectiveness across settings to inform guideline updates.
METHODS: In an ongoing international Bayesian adaptive platform trial, we conducted an open-label, randomized comparison of cefazolin with an antistaphylococcal penicillin (flucloxacillin or cloxacillin) in adult patients with penicillin-resistant, methicillin-susceptible RESULTS: This domain of the ongoing trial was conducted between February 17, 2022, and August 7, 2024, by which time the criterion for noninferiority had been met. Mortality at 90 days among adults who could be evaluated was 15.0% (97 deaths among 645 patients) in the cefazolin group and 17.0% (109 deaths among 642 patients) in the antistaphylococcal-penicillin group (adjusted odds ratio, 0.81; 95% credible interval, 0.59 to 1.12; probability of noninferiority, 99.2%; probability of superiority, 89.8%). Acute kidney injury occurred in 92 of 660 patients (13.9%) in the cefazolin group, as compared with 127 of 648 (19.6%) in the antistaphylococcal-penicillin group (adjusted odds ratio, 0.67; 95% credible interval, 0.50 to 0.89; probability of superiority, 99.7%). CONCLUSIONS: In patients with methicillin-susceptible
2. Individualised duration of antibiotic treatment in culture-negative early-onset sepsis in late-preterm and term-born neonates in Denmark (DURATION): a multicentre, open-label, randomised, controlled, non-inferiority trial.
In this nationwide multicentre RCT, clinically guided individualized duration for culture-negative early-onset neonatal sepsis was noninferior to standard 5–7 days regarding infection-related readmission and reduced antibiotic exposure to a median of 3 days. The approach integrates serial clinical assessment and CRP trajectory.
Impact: Provides high-quality evidence to shorten antibiotic duration safely in probable EOS, directly advancing antimicrobial stewardship in a high-use neonatal population.
Clinical Implications: Neonatal services can adopt individualized stop rules (no ongoing signs, CRP ≤30 mg/L and declining after 24 h) to reduce treatment duration to ~3 days in culture-negative EOS, with monitoring pathways to ensure safety.
Key Findings
- Randomized 493 neonates (246 individualized vs 247 standard) among 811 eligible across Denmark.
- Readmission due to bacterial infection: 1% (2/246) individualized vs <1% (1/247) standard; risk difference 0.4% (95% CI -1.5 to 2.6), meeting noninferiority.
- Total antibiotic duration reduced to a median of 3 days in the individualized arm versus 5–7 days standard.
Methodological Strengths
- Pragmatic nationwide multicentre RCT with prespecified noninferiority margin and dual coprimary outcomes.
- Applied both intention-to-treat and per-protocol analyses with clear stopping criteria based on CRP kinetics and clinical status.
Limitations
- Open-label design and very low event rates may limit precision around rare harms.
- Follow-up window for readmission is not detailed in the abstract, and generalizability to low-resource settings requires evaluation.
Future Directions: Validate in diverse health systems, refine biomarker thresholds and monitoring frequency, and assess impacts on microbiome, resistance, and long-term neurodevelopment.
BACKGROUND: Suspicion of early-onset sepsis (EOS) is a major contributor to antibiotic use in late-preterm and term-born neonates. We aimed to evaluate whether a clinically guided, individualised approach to treatment duration could safely reduce antibiotic exposure compared with standard care. METHODS: This nationwide, multicentre, open-label, randomised, controlled, non-inferiority trial included late-preterm and term-born neonates (aged 0-3 days, gestational age 35 weeks or more, birthweight 2000 g or more) with culture-negative early-onset sepsis (probable EOS), defined as continuation of antibiotic treatment beyond 36-48 h based on clinical signs of or maternal risk factors for infection in combination with elevated C-reactive protein and symptom onset less than 72 h after birth. Neonates were ineligible if they met the criteria for discontinuing antibiotics before 48 h. Participants were randomised (1:1) to individualised or standard treatment. In the individualised group, antibiotic treatment was discontinued after 24 h without clinical signs of infection, provided that C-reactive protein was declining to ≤30 mg/L. Standard treatment was 5-7 days. The coprimary outcomes were readmission due to bacterial infection (non-inferiority margin 4%) and total antibiotic duration (superiority assessment), performed on both intention-to-treat and per-protocol populations. Safety was assessed in all included neonates. This study was registered with ClinicalTrials.gov (NCT05329701) and is completed. FINDINGS: Between April 22, 2022, and April 5, 2025, 493 (61%) of 811 eligible neonates were randomly assigned to individualised (n=246) or standard (n=247) duration. Antibiotic therapy was initiated at a median of 22·5 h (IQR 14·4-28·0) after birth in the individualised group and 24·5 h (16·6-28·0) in the standard group. Readmission due to bacterial infection occurred in two (1%) of 246 neonates in the individualised group and one (<1%) of 247 in the standard group (risk difference 0·4% [95% CI -1·5 to 2·6]; p INTERPRETATION: In neonates with probable EOS, a clinically guided, individualised treatment strategy was non-inferior to standard therapy with respect to infection-related readmission and reduced treatment duration to a median of 3 days. These findings support reduced antibiotic use through individualised treatment duration strategies. FUNDING: Copenhagen University Hospital Rigshospitalet Research Fund, Innovation Fund Denmark, and Greater Copenhagen Health Science Partners.
3. Engineered antibodies bypass bacterial immune evasion to drive complement-mediated protection against lethal infections.
Engineered T-CAT monoclonal antibodies initiate complement activation directly on bacterial surfaces, circumventing classical pathway C1 and overcoming pathogen evasion. In murine sepsis and pneumonia models, T-CAT conferred safe and effective protection, highlighting a translational path for antibody-based anti-infectives.
Impact: First-in-class strategy to enzymatically trigger complement on pathogens offers a mechanistically distinct immunotherapy against resistant infections, including sepsis.
Clinical Implications: While preclinical, T-CAT could complement antibiotics for multidrug-resistant sepsis and pneumonia by restoring effective complement-mediated killing; safety, dosing, and spectrum require human trials.
Key Findings
- Developed T-CAT mAbs with enzymatic capability to initiate complement directly on bacterial surfaces, bypassing classical pathway C1.
- T-CAT overcame pathogen immune evasion that limits classical pathway activation and clearance.
- In murine models of sepsis and pneumonia, T-CAT treatment was safe and effective, providing protection against lethal infection.
Methodological Strengths
- Mechanistic innovation with functional validation across in vivo sepsis and pneumonia models.
- Directly addresses known failure mode of classical complement activation by engineering a bypass.
Limitations
- Preclinical murine data; human immunogenicity, pharmacokinetics, and complement-related safety remain unknown.
- Spectrum-of-activity and resistance potential under clinical conditions require characterization.
Future Directions: Advance to first-in-human studies to assess safety, dosing, and efficacy; expand target panels across Gram-positive and Gram-negative pathogens and evaluate synergy with antibiotics.
The expanding global crisis of bacterial infections caused by antimicrobial-resistant pathogens has resulted in an urgent need for therapeutics. Previous efforts to target pathogen surface antigens with monoclonal antibodies (mAbs) have sought to activate the complement system, primarily through the antibody-dependent classical pathway. However, most mAbs have induced insufficient complement activation because pathogen evasion strategies disrupt the complex spatiotemporal requirements for activation of the classical pathway initiation complex C1. To address this, we developed a targeted complement activation therapy (T-CAT), which uses antibodies furnished with the enzymatic capability to initiate complement activation directly on the bacterial surface without involvement of the classical pathway initiation complex. We found that T-CAT mAbs directed against bacterial surface antigens can overcome the strategies that pathogens evolved to escape from classical pathway-mediated clearance by the immune system. We further demonstrated that T-CAT mAbs could safely and effectively be used to treat infectious disease in experimental murine models of sepsis and pneumonia caused by